Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

HMS faculty, help us improve the algorithms in Profiles by uploading your CV!

Cristina Rosa Ferrone, M.D.

Co-Author

This page shows the publications co-authored by Cristina Ferrone and Theodore Hong.
Connection Strength

5.887
  1. Tumor Microenvironment Immune Response in Pancreatic Ductal Adenocarcinoma Patients Treated With Neoadjuvant Therapy. J Natl Cancer Inst. 2021 02 01; 113(2):182-191.
    View in: PubMed
    Score: 0.223
  2. Conditional Survival in Resected Pancreatic Ductal Adenocarcinoma Patients Treated with Total Neoadjuvant Therapy. J Gastrointest Surg. 2021 11; 25(11):2859-2870.
    View in: PubMed
    Score: 0.222
  3. Intraoperative Radiation Mitigates the Effect of Microscopically Positive Tumor Margins on Survival Among Pancreatic Adenocarcinoma Patients Treated with Neoadjuvant FOLFIRINOX and Chemoradiation. Ann Surg Oncol. 2021 Aug; 28(8):4592-4601.
    View in: PubMed
    Score: 0.221
  4. Prospective Phase II Trials Validate the Effect of Neoadjuvant Chemotherapy on Pattern of Recurrence in Pancreatic Adenocarcinoma. Ann Surg. 2020 Oct 19.
    View in: PubMed
    Score: 0.218
  5. Palliative External Beam Radiation Therapy for Hepatocellular Carcinoma With Right Atrial Tumor Thrombus. Pract Radiat Oncol. 2020 May - Jun; 10(3):e183-e187.
    View in: PubMed
    Score: 0.207
  6. Management implications of fluorodeoxyglucose positron emission tomography/magnetic resonance in untreated intrahepatic cholangiocarcinoma. Eur J Nucl Med Mol Imaging. 2020 07; 47(8):1871-1884.
    View in: PubMed
    Score: 0.204
  7. Total Neoadjuvant Therapy With FOLFIRINOX in Combination With Losartan Followed by Chemoradiotherapy for Locally Advanced Pancreatic Cancer: A Phase 2 Clinical Trial. JAMA Oncol. 2019 Jul 01; 5(7):1020-1027.
    View in: PubMed
    Score: 0.199
  8. Predictors of Resectability and Survival in Patients With Borderline and Locally Advanced Pancreatic Cancer who Underwent Neoadjuvant Treatment With FOLFIRINOX. Ann Surg. 2019 04; 269(4):733-740.
    View in: PubMed
    Score: 0.196
  9. Protons versus Photons for Unresectable Hepatocellular Carcinoma: Liver Decompensation and Overall Survival. Int J Radiat Oncol Biol Phys. 2019 09 01; 105(1):64-72.
    View in: PubMed
    Score: 0.193
  10. Are Staging Computed Tomography (CT) Scans of the Chest Necessary in Pancreatic Adenocarcinoma? Ann Surg Oncol. 2018 Dec; 25(13):3936-3942.
    View in: PubMed
    Score: 0.189
  11. Total Neoadjuvant Therapy With FOLFIRINOX Followed by Individualized Chemoradiotherapy for Borderline Resectable Pancreatic Adenocarcinoma: A Phase 2 Clinical Trial. JAMA Oncol. 2018 07 01; 4(7):963-969.
    View in: PubMed
    Score: 0.186
  12. Tolerability and Long-term Outcomes of Dose-Painted Neoadjuvant Chemoradiation to Regions of Vessel Involvement in Borderline or Locally Advanced Pancreatic Cancer. Am J Clin Oncol. 2018 07; 41(7):656-661.
    View in: PubMed
    Score: 0.186
  13. Intraoperative Radiotherapy in the Era of Intensive Neoadjuvant Chemotherapy and Chemoradiotherapy for Pancreatic Adenocarcinoma. Am J Clin Oncol. 2018 06; 41(6):607-612.
    View in: PubMed
    Score: 0.185
  14. Liver reirradiation for patients with hepatocellular carcinoma and liver metastasis. Pract Radiat Oncol. 2018 Nov - Dec; 8(6):414-421.
    View in: PubMed
    Score: 0.184
  15. Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype. J Natl Cancer Inst. 2017 09 01; 109(9).
    View in: PubMed
    Score: 0.176
  16. Multi-Institutional Phase II Study of High-Dose Hypofractionated Proton Beam Therapy in Patients With Localized, Unresectable Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma. J Clin Oncol. 2016 Feb 10; 34(5):460-8.
    View in: PubMed
    Score: 0.156
  17. PD-L1 and HLA Class I Antigen Expression and Clinical Course of the Disease in Intrahepatic Cholangiocarcinoma. Clin Cancer Res. 2016 Jan 15; 22(2):470-8.
    View in: PubMed
    Score: 0.153
  18. Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer. Ann Surg. 2015 Jan; 261(1):12-7.
    View in: PubMed
    Score: 0.146
  19. A phase 1/2 and biomarker study of preoperative short course chemoradiation with proton beam therapy and capecitabine followed by early surgery for resectable pancreatic ductal adenocarcinoma. Int J Radiat Oncol Biol Phys. 2014 Jul 15; 89(4):830-8.
    View in: PubMed
    Score: 0.140
  20. Phase I study of neoadjuvant accelerated short course radiation therapy with photons and capecitabine for resectable pancreatic cancer. Radiother Oncol. 2014 Jan; 110(1):160-4.
    View in: PubMed
    Score: 0.135
  21. Surgical placement of biologic mesh spacers to displace bowel away from unresectable liver tumors followed by delivery of dose-intense radiation therapy. Pract Radiat Oncol. 2014 May-Jun; 4(3):167-173.
    View in: PubMed
    Score: 0.133
  22. Delaying chemoradiation until after completion of adjuvant chemotherapy for pancreatic cancer may not impact local control. Pract Radiat Oncol. 2014 Mar-Apr; 4(2):e117-e123.
    View in: PubMed
    Score: 0.133
  23. FOLFIRINOX in locally advanced pancreatic cancer: the Massachusetts General Hospital Cancer Center experience. Oncologist. 2013; 18(5):543-8.
    View in: PubMed
    Score: 0.130
  24. Pancreatic ductal adenocarcinoma: is there a survival difference for R1 resections versus locally advanced unresectable tumors? What is a "true" R0 resection? Ann Surg. 2013 Apr; 257(4):731-6.
    View in: PubMed
    Score: 0.129
  25. Pancreatic neuroendocrine tumors with involved surgical margins: prognostic factors and the role of adjuvant radiotherapy. Int J Radiat Oncol Biol Phys. 2012 Jul 01; 83(3):e337-43.
    View in: PubMed
    Score: 0.120
  26. Single-nucleus and spatial transcriptome profiling of pancreatic cancer identifies multicellular dynamics associated with neoadjuvant treatment. Nat Genet. 2022 08; 54(8):1178-1191.
    View in: PubMed
    Score: 0.062
  27. Positron Emission Tomography/Magnetic Resonance Imaging Versus the Standard of Care Imaging in the Diagnosis of Peritoneal Carcinomatosis. Ann Surg. 2022 Feb 17.
    View in: PubMed
    Score: 0.060
  28. A Combination of Biochemical and Pathological Parameters Improves Prediction of Postresection Survival After Preoperative Chemotherapy in Pancreatic Cancer: The PANAMA-score. Ann Surg. 2022 02 01; 275(2):391-397.
    View in: PubMed
    Score: 0.060
  29. Underlying Bias in the Treatment of Pancreatic Cancer: Minorities Treated at the Same Facilities are Less Likely to Receive Neoadjuvant Therapy. Ann Surg. 2021 Dec 23.
    View in: PubMed
    Score: 0.059
  30. Arterial involvement and resectability scoring system to predict R0 resection in patients with pancreatic ductal adenocarcinoma treated with neoadjuvant chemoradiation therapy. Eur Radiol. 2022 Apr; 32(4):2470-2480.
    View in: PubMed
    Score: 0.058
  31. Value of Neoadjuvant Radiation Therapy in the Management of Pancreatic Adenocarcinoma. J Clin Oncol. 2021 12 01; 39(34):3773-3777.
    View in: PubMed
    Score: 0.058
  32. Clinical impact of PET/MRI in oligometastatic colorectal cancer. Br J Cancer. 2021 09; 125(7):975-982.
    View in: PubMed
    Score: 0.057
  33. Minimal Residual Disease Detection using a Plasma-only Circulating Tumor DNA Assay in Patients with Colorectal Cancer. Clin Cancer Res. 2021 10 15; 27(20):5586-5594.
    View in: PubMed
    Score: 0.057
  34. Impact of PET/MRI in the Treatment of Pancreatic Adenocarcinoma: a Retrospective Cohort Study. Mol Imaging Biol. 2021 06; 23(3):456-466.
    View in: PubMed
    Score: 0.055
  35. Evaluation of Pathologic Response on Overall Survival After Neoadjuvant Therapy in Pancreatic Ductal Adenocarcinoma. Pancreas. 2020 08; 49(7):897-903.
    View in: PubMed
    Score: 0.054
  36. Patterns of Failure and the Need for Biliary Intervention in Resected Biliary Tract Cancers After Chemoradiation. Ann Surg Oncol. 2020 Dec; 27(13):5161-5172.
    View in: PubMed
    Score: 0.054
  37. Pancreatic ductal adenocarcinoma: tumour regression grading following neoadjuvant FOLFIRINOX and radiation. Histopathology. 2020 Jul; 77(1):35-45.
    View in: PubMed
    Score: 0.053
  38. Impact of adjuvant therapy in patients with invasive intraductal papillary mucinous neoplasms of the pancreas. Pancreatology. 2020 Jun; 20(4):722-728.
    View in: PubMed
    Score: 0.052
  39. Clinical staging in pancreatic adenocarcinoma underestimates extent of disease. Pancreatology. 2020 Jun; 20(4):691-697.
    View in: PubMed
    Score: 0.052
  40. Socioeconomic determinants of the surgical treatment of colorectal liver metastases. Am J Surg. 2020 10; 220(4):952-957.
    View in: PubMed
    Score: 0.052
  41. Hypofractionated Radiation Therapy for Unresectable/Locally Recurrent Intrahepatic Cholangiocarcinoma. Ann Surg Oncol. 2020 Apr; 27(4):1122-1129.
    View in: PubMed
    Score: 0.052
  42. Epithelial to mesenchymal plasticity and differential response to therapies in pancreatic ductal adenocarcinoma. Proc Natl Acad Sci U S A. 2019 12 16.
    View in: PubMed
    Score: 0.051
  43. Intraoperative Radiation Therapy (IORT) for Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma (BR/LA PDAC) in the Era of Modern Neoadjuvant Treatment: Short-Term and Long-Term Outcomes. Ann Surg Oncol. 2020 May; 27(5):1400-1406.
    View in: PubMed
    Score: 0.051
  44. Clinical impact of PET/MR in treated colorectal cancer patients. Eur J Nucl Med Mol Imaging. 2019 Oct; 46(11):2260-2269.
    View in: PubMed
    Score: 0.050
  45. Predictors of adjuvant treatment and survival in patients with intrahepatic cholangiocarcinoma who undergo resection. Am J Surg. 2019 11; 218(5):959-966.
    View in: PubMed
    Score: 0.049
  46. Quasimesenchymal phenotype predicts systemic metastasis in pancreatic ductal adenocarcinoma. Mod Pathol. 2019 06; 32(6):844-854.
    View in: PubMed
    Score: 0.048
  47. Neoadjuvant FOLFIRINOX for Patients with Borderline Resectable or Locally Advanced Pancreatic Cancer: Results of a Decision Analysis. Oncologist. 2019 07; 24(7):945-954.
    View in: PubMed
    Score: 0.048
  48. Association Between Very Small Tumor Size and Decreased Overall Survival in Node-Positive Pancreatic Cancer. Ann Surg Oncol. 2018 Dec; 25(13):4027-4034.
    View in: PubMed
    Score: 0.047
  49. Hepatocellular Carcinoma with Macrovascular Invasion: Defining the Optimal Treatment Strategy. Liver Cancer. 2017 Nov; 6(4):360-374.
    View in: PubMed
    Score: 0.044
  50. A novel chemoradiation targeting stem and nonstem pancreatic cancer cells by repurposing disulfiram. Cancer Lett. 2017 11 28; 409:9-19.
    View in: PubMed
    Score: 0.044
  51. Use of Angiotensin System Inhibitors Is Associated with Immune Activation and Longer Survival in Nonmetastatic Pancreatic Ductal Adenocarcinoma. Clin Cancer Res. 2017 Oct 01; 23(19):5959-5969.
    View in: PubMed
    Score: 0.043
  52. Predictors of Early Mortality After Surgical Resection of Pancreatic Adenocarcinoma in the Era of Neoadjuvant Treatment. Pancreas. 2017 02; 46(2):183-189.
    View in: PubMed
    Score: 0.042
  53. Prognosis and Clinicopathologic Features of Patients With Advanced Stage Isocitrate Dehydrogenase (IDH) Mutant and IDH Wild-Type Intrahepatic Cholangiocarcinoma. Oncologist. 2015 Sep; 20(9):1019-27.
    View in: PubMed
    Score: 0.038
  54. Circulating oncometabolite 2-hydroxyglutarate is a potential surrogate biomarker in patients with isocitrate dehydrogenase-mutant intrahepatic cholangiocarcinoma. Clin Cancer Res. 2014 Apr 01; 20(7):1884-90.
    View in: PubMed
    Score: 0.034
  55. Updated long-term outcomes and prognostic factors for patients with unresectable locally advanced pancreatic cancer treated with intraoperative radiotherapy at the Massachusetts General Hospital, 1978 to 2010. Cancer. 2013 Dec 01; 119(23):4196-204.
    View in: PubMed
    Score: 0.033
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.